Polaryx Therapeutics, Inc. Common Stock

FRC's fair value estimate for Polaryx Therapeutics, Inc. Common Stock, and the rating behind it. PLYX last traded at $2.09; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Polaryx Therapeutics, Inc. Common Stock. Starting points for Polaryx Therapeutics, Inc. Common Stock: EPS -$0.14, beta -9.26 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Polaryx Therapeutics, Inc. Common Stock. Polaryx Therapeutics, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Polaryx Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Polaryx Therapeutics, Inc. Common Stock stands at -$0.14. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Polaryx Therapeutics, Inc. Common Stock. Polaryx Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Polaryx Therapeutics, Inc. Common Stock valued side by side against its closest peers. Polaryx Therapeutics, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Polaryx Therapeutics, Inc. Common Stock, and how their positions are changing. At a $104.2M market value, institutional positions materially move Polaryx Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Polaryx Therapeutics, Inc. Common Stock executives and directors. Shares of Polaryx Therapeutics, Inc. Common Stock have traded between $1.86 and $48.91 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Polaryx Therapeutics, Inc. Common Stock. Polaryx Therapeutics, Inc. Common Stock is a $104.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Polaryx Therapeutics, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Polaryx Therapeutics, Inc. Common Stock. Coverage tracks Polaryx Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.